These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 19389561)

  • 1. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
    Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
    J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
    Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Murphy SA; Budaj A; Varshavsky S; Wolff AA; Skene A; McCabe CH; Braunwald E;
    JAMA; 2007 Apr; 297(16):1775-83. PubMed ID: 17456819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
    Melloni C; Newby LK
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36).
    Mega JL; Hochman JS; Scirica BM; Murphy SA; Sloan S; McCabe CH; Merlini P; Morrow DA
    Circulation; 2010 Apr; 121(16):1809-17. PubMed ID: 20385930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial.
    Scirica BM; Morrow DA; Budaj A; Dalby AJ; Mohanavelu S; Qin J; Aroesty J; Hedgepeth CM; Stone PH; Braunwald E
    J Am Coll Cardiol; 2009 Apr; 53(16):1411-21. PubMed ID: 19371824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial.
    Morrow DA; Scirica BM; Sabatine MS; de Lemos JA; Murphy SA; Jarolim P; Theroux P; Bode C; Braunwald E
    J Am Coll Cardiol; 2010 Mar; 55(12):1189-1196. PubMed ID: 20298924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial.
    Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Skene A; McCabe CH; Braunwald E;
    Am Heart J; 2006 Jun; 151(6):1186.e1-9. PubMed ID: 16781216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
    Scirica BM; Morrow DA; Hod H; Murphy SA; Belardinelli L; Hedgepeth CM; Molhoek P; Verheugt FW; Gersh BJ; McCabe CH; Braunwald E
    Circulation; 2007 Oct; 116(15):1647-52. PubMed ID: 17804441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 Trial.
    Gutierrez JA; Karwatowska-Prokopczuk E; Murphy SA; Belardinelli L; Farzaneh-Far R; Walker G; Morrow DA; Scirica BM
    Clin Cardiol; 2015 Aug; 38(8):469-75. PubMed ID: 26059896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial.
    Arnold SV; Morrow DA; Wang K; Lei Y; Mahoney EM; Scirica BM; Braunwald E; Cohen DJ;
    Circ Cardiovasc Qual Outcomes; 2008 Nov; 1(2):107-15. PubMed ID: 20031797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
    Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
    JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes.
    Bonaca MP; Scirica BM; Sabatine MS; Jarolim P; Murphy SA; Chamberlin JS; Rhodes DW; Southwick PC; Braunwald E; Morrow DA
    J Am Coll Cardiol; 2012 Jul; 60(4):332-8. PubMed ID: 22813612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36).
    O'Malley RG; Bonaca MP; Scirica BM; Murphy SA; Jarolim P; Sabatine MS; Braunwald E; Morrow DA
    J Am Coll Cardiol; 2014 Apr; 63(16):1644-53. PubMed ID: 24530676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
    Thadani U; Ezekowitz M; Fenney L; Chiang YK
    Circulation; 1994 Aug; 90(2):726-34. PubMed ID: 8044941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.
    Rousseau MF; Pouleur H; Cocco G; Wolff AA
    Am J Cardiol; 2005 Feb; 95(3):311-6. PubMed ID: 15670536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranolazine in patients with angina and coronary artery disease.
    Scirica BM; Morrow DA
    Curr Cardiol Rep; 2007 Jul; 9(4):272-8. PubMed ID: 17601393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranolazine for the management of coronary artery disease.
    Cheng JW
    Clin Ther; 2006 Dec; 28(12):1996-2007. PubMed ID: 17296457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
    Chaitman BR; Skettino SL; Parker JO; Hanley P; Meluzin J; Kuch J; Pepine CJ; Wang W; Nelson JJ; Hebert DA; Wolff AA;
    J Am Coll Cardiol; 2004 Apr; 43(8):1375-82. PubMed ID: 15093870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranolazine in patients with coronary artery disease.
    Scirica BM
    Expert Opin Pharmacother; 2007 Sep; 8(13):2149-57. PubMed ID: 17714067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine.
    Karwatowska-Prokopczuk E; Wang W; Cheng ML; Zeng D; Schwartz PJ; Belardinelli L
    Europace; 2013 Mar; 15(3):429-36. PubMed ID: 23258816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.